RNS Number : 1384V
Valereum PLC
30 November 2023

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR")

30/11/2023

Valereum Plc

("Valereum" or the **"Company")**

New Board Appointment

Valereum Plc (AQUIS: VLRM), the Gibraltar technology group, is today announcing the following new board appointment:

Karl Moss will be joining the Company as Chief Financial Officer (CFO). Karl brings 30 years' experience across financial planning, compliance and corporate finance, including 20 years' Board experience as CFO, delivering sector leading growth leading to significant realisations in shareholder value in the SAL Group and the i2 Group.

The following information is provided for the purpose of Rule 4.9 of the AQSE Growth Market Access Rulebook for Karl Moss.

Current directorships and/or partnerships:	Former directorships and/or partnerships (within the last five years):
I2 Analytical Limited Scientific Analysis Instruments Limited Gatenet Technology Limited Mycotoxin Laboratory UK Ltd I2 Fast Limited Hallco (479) Limited	None

Karl was Financial Director of REC CHSS Training Limited and its dormant parent holding company Corporate Health & Safety Services Limited. Karl resigned from the company on 19th July 2013. The parent company went into administration on 11th March 2014 following a failed MBO by the management team in preparation for a divestment of the wider group company.

There is no further information to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

The Directors of the Company accept responsibility for the contents of this announcement.

For more information, please visit the Company's website at Valereum.gi

Enquiries:
Valereum Plc
James Formolli, Chairman
Tel: +971 4584 6284

AQSE Corporate Adviser
First Sentinel Corporate Finance
Brian Stockbridge
Tel: +44 20 3855 5551

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFEMEFUEDSELF